The gut microbiome as a potential source of non-invasive biomarkers of chronic obstructive pulmonary disease.
COPD
biomarker
diagnosis
gut microbiome
metagenomics
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
02
2023
accepted:
12
07
2023
medline:
9
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
The link between gut microbial dysbiosis and the development of chronic obstructive pulmonary disease (COPD) is of considerable interest. However, little is known regarding the potential for the use of the fecal metagenome for the diagnosis of COPD. A total of 80 healthy controls, 31 patients with COPD severity stages I or II, and 49 patients with COPD severity stages III or IV fecal samples were subjected to metagenomic analysis. We characterized the gut microbiome, identified microbial taxonomic and functional markers, and constructed a COPD disease classifier using samples. The fecal microbial diversity of patients with COPD stages I or II was higher than that of healthy controls, but lower in patients with COPD stages III or IV. Twenty-one, twenty-four, and eleven microbial species, including potential pathogens and pro-inflammatory bacteria, were significantly enriched or depleted in healthy controls, patients with COPD stages I or II, and patients with COPD stages III & IV. The KEGG orthology (KO) gene profiles derived demonstrated notable differences in gut microbial function among the three groups. Moreover, gut microbial taxonomic and functional markers could be used to differentiate patients with COPD from healthy controls, on the basis of areas under receiver operating characteristic curves (AUCs) of 0.8814 and 0.8479, respectively. Notably, the gut microbial taxonomic features differed between healthy individuals and patients in stages I-II COPD, which suggests the utility of fecal metagenomic biomarkers for the diagnosis of COPD (AUC = 0.9207). Gut microbiota-targeted biomarkers represent potential non-invasive tools for the diagnosis of COPD.
Sections du résumé
Background
UNASSIGNED
The link between gut microbial dysbiosis and the development of chronic obstructive pulmonary disease (COPD) is of considerable interest. However, little is known regarding the potential for the use of the fecal metagenome for the diagnosis of COPD.
Methods
UNASSIGNED
A total of 80 healthy controls, 31 patients with COPD severity stages I or II, and 49 patients with COPD severity stages III or IV fecal samples were subjected to metagenomic analysis. We characterized the gut microbiome, identified microbial taxonomic and functional markers, and constructed a COPD disease classifier using samples.
Results
UNASSIGNED
The fecal microbial diversity of patients with COPD stages I or II was higher than that of healthy controls, but lower in patients with COPD stages III or IV. Twenty-one, twenty-four, and eleven microbial species, including potential pathogens and pro-inflammatory bacteria, were significantly enriched or depleted in healthy controls, patients with COPD stages I or II, and patients with COPD stages III & IV. The KEGG orthology (KO) gene profiles derived demonstrated notable differences in gut microbial function among the three groups. Moreover, gut microbial taxonomic and functional markers could be used to differentiate patients with COPD from healthy controls, on the basis of areas under receiver operating characteristic curves (AUCs) of 0.8814 and 0.8479, respectively. Notably, the gut microbial taxonomic features differed between healthy individuals and patients in stages I-II COPD, which suggests the utility of fecal metagenomic biomarkers for the diagnosis of COPD (AUC = 0.9207).
Conclusion
UNASSIGNED
Gut microbiota-targeted biomarkers represent potential non-invasive tools for the diagnosis of COPD.
Identifiants
pubmed: 37555072
doi: 10.3389/fmicb.2023.1173614
pmc: PMC10405926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1173614Informations de copyright
Copyright © 2023 Li, Yi, Chen, Dai, Deng, Pu, Zhou, Li, Wang and Ran.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Respir Med. 2018 Jun;6(6):421-430
pubmed: 29650407
Hepatology. 2020 Jul;72(1):271-286
pubmed: 32056227
Respir Res. 2020 Oct 19;21(1):271
pubmed: 33076910
ISME J. 2020 Jul;14(7):1639-1650
pubmed: 32210364
Med Res Rev. 2019 Nov;39(6):2286-2313
pubmed: 30994937
Gut. 2017 Jan;66(1):70-78
pubmed: 26408641
Lancet. 2018 Apr 28;391(10131):1706-1717
pubmed: 29650248
Nat Med. 2020 Nov;26(11):1766-1775
pubmed: 33139948
Sci Transl Med. 2022 Jun 15;14(649):eabl3981
pubmed: 35704600
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1131-1141
pubmed: 31718748
Neurology. 2022 Feb 22;98(8):e848-e858
pubmed: 34996879
Respir Res. 2021 Oct 25;22(1):274
pubmed: 34696775
PLoS Med. 2014 Mar 25;11(3):e1001621
pubmed: 24667834
Thorax. 2017 Sep;72(9):788-795
pubmed: 27941160
ERJ Open Res. 2019 Feb 18;5(1):
pubmed: 30792986
Nat Commun. 2015 Mar 11;6:6528
pubmed: 25758642
Bioinformatics. 2006 Jul 1;22(13):1658-9
pubmed: 16731699
Microbiome. 2019 Mar 22;7(1):46
pubmed: 30902113
Cancer Discov. 2022 Aug 5;12(8):1873-1885
pubmed: 35678528
Int J Mol Sci. 2022 Apr 26;23(9):
pubmed: 35563159
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Gut. 2019 Jun;68(6):1014-1023
pubmed: 30045880
Am J Respir Crit Care Med. 2007 Oct 15;176(8):753-60
pubmed: 17575095
Bioinformatics. 2015 May 15;31(10):1674-6
pubmed: 25609793
Front Nutr. 2021 Feb 04;7:610946
pubmed: 33614691
Gigascience. 2019 Aug 1;8(8):
pubmed: 31367746
Gut. 2022 Feb;71(2):309-321
pubmed: 33687943
Gut Microbes. 2020 Jul 3;11(4):1030-1042
pubmed: 32240032
Ann Rheum Dis. 2022 Aug 19;:
pubmed: 35985811
Microbiome. 2022 Feb 21;10(1):35
pubmed: 35189961
Nat Methods. 2015 Jan;12(1):59-60
pubmed: 25402007
Gut. 2023 Jun;72(6):1129-1142
pubmed: 35953094
Bioinformatics. 2012 Sep 1;28(17):2223-30
pubmed: 22796954
N Engl J Med. 2017 Sep 7;377(10):923-935
pubmed: 28877027
Gigascience. 2018 Mar 1;7(3):1-8
pubmed: 29293960
Nat Biotechnol. 2014 Aug;32(8):834-41
pubmed: 24997786
N Engl J Med. 2020 Apr 2;382(14):1320-1330
pubmed: 32242357
Gigascience. 2017 May 1;6(5):1-9
pubmed: 28379488
PeerJ. 2015 Aug 27;3:e1165
pubmed: 26336640
Nat Commun. 2020 Nov 18;11(1):5886
pubmed: 33208745